



1 June 2020

ASX Announcement

Phillip Lynch appointed Director of Race

- **Mr Phillip Lynch, former Vice President Commercial Growth & Innovation for Johnson & Johnson Asia Pacific, joins Race as Non-Executive Director**
- **Appointment brings further, deep commercial experience to Race's Board**
- **Mr Lynch to strengthen Race's outreach in the Asia Pacific region**

1 June 2020 – Race Oncology Limited (ASX: RAC) is pleased to announce that Mr Phillip R Lynch has been appointed to the Board as an independent Non-Executive Director.

Mr Lynch joins Race following a career spanning more than 30 years in the Asia Pacific region with Johnson & Johnson. He is an experienced executive and board director, with a diverse background across corporate development, strategy, financial performance, marketing and governance.

In his former role as Vice President of Commercial Growth & Innovation at Johnson & Johnson Asia Pacific (J&J AP, 2016 - 2019), Mr Lynch partnered with the Mergers & Acquisitions team to drive the integration and growth of acquired businesses. He retired from J&J AP in December 2019 following the >\$2b acquisition and integration of a significant Japanese business.

Mr Lynch was previously the Managing Director and CEO of J&J Pacific (AU/NZ) where he led J&J Pacific to significant growth in revenue and profitability (2009 to 2015). He had further leadership roles across the Asia Pacific region, including Managing Director of various J&J divisions in Thailand, Vietnam and Singapore.

Phillip was also a member of the J&J Corporate Australian Board working across the Consumer, Medical and Pharmaceutical businesses. He was Non-Executive Director of a US based e-commerce Logistics start up that was successfully scaled and sold in 2013.

Mr Lynch is a graduate of Monash University with a Bachelor of Business in Marketing. He has completed post-graduate studies at University of Virginia's Darden Business School (USA) and is a Graduate of the Australian Institute of Company Directors.

"We welcome Phil to the Race team and we all look forward to working with him as we move Race forward. His experience in M&A and corporate strategy in the Asia Pacific region will be a huge asset to Race as we execute on our 5-Path strategy." said Race Oncology Executive Chairman, Dr John Cullity.

Mr Phillip Lynch commented, "Race brings together a highly capable team and a developed strategy for its differentiated drug which possesses clear activity in leukemia and the promise of additional treatment applications. I look forward to joining the Board and working with the team to see Bisantrene commercialised globally benefitting cancer patients and the business' broader stakeholders."

- ENDS -

About Race Oncology (ASX: RAC)

Race Oncology (RAC) is a drug development biotech with a Phase II/III cancer drug called Bisantrene. RAC has compelling clinical data for Bisantrene in acute myeloid leukaemia (AML) as well as breast and ovarian cancer. RAC is pursuing an exciting '5-Path' clinical development strategy that involves parallel US and Australian clinical trials in AML, breast and ovarian with clinical trials to begin in 2020.

Release authorised by:

John Cullity, Executive Chairman

john@biosynergypartners.com

Dr Daniel Tillett, Chief Operating Officer & Director

daniel.tillett@raceoncology.com

Media contact:

Henry Jordan, Six Degrees Investor Relations

+61 411 272 366

henry.jordan@sdir.com.au